Incretin-based drugs decrease the incidence of prostate cancer in type 2 diabetics: A pooling-up analysis

作者全名：Lin, Yuxiang; Xu, Guangyong; Li, Liangyu; Xiang, Jingyi; Zhai, Lingyun

作者地址：[Lin, Yuxiang; Xu, Guangyong; Li, Liangyu; Zhai, Lingyun] Chongqing Med Univ, Affiliated Hosp 2, Dept Urol, Chongqing 400072, Peoples R China; [Xiang, Jingyi] Chongqing Med Univ, Affiliated Hosp 2, Inst Viral Hepatitis, Dept Infect Dis,Key Lab Mol Biol Infect Dis,Minist, Chongqing, Peoples R China

通信作者：Zhai, LY (通讯作者)，Chongqing Med Univ, Affiliated Hosp 2, Dept Urol, Chongqing 400072, Peoples R China.

来源：MEDICINE

ESI学科分类：CLINICAL MEDICINE

WOS号：WOS:001226575400002

JCR分区：Q2

影响因子：1.3

年份：2024

卷号：103

期号：20

开始页：　

结束页：　

文献类型：Article

关键词：based drugs; DPP-4; GLP-1; incretin; prostate cancer

摘要：Incretin-based drugs, a class of Antidiabetic medications (ADMs) used in the treatment of type 2 diabetes, may affect the incidence of prostate cancer (PCa). But real-world evidence for this possible effect is lacking. Therefore, the aim of this study is to assess the effect of incretin-based drugs on the incidence of PCa, including glucagon-like peptide-1 (GLP-1) receptor agonists and dipeptidyl peptidase-4 (DPP-4) inhibitors. We searched PubMed, Embase, and Cochrane Library databases for eligible studies through September 2023. Two independent reviewers performed screening and data extraction. We used the Cochrane Handbook for Systematic Reviews and the Newcastle-Ottawa Scale (NOS) to assess the quality of included randomized controlled trials (RCTs) and cohort studies. We did a meta-analysis of available trial data to calculate overall risk ratios (RRs) for PCa. A total of 1238 articles were identified in our search. After screening for eligibility, 7 high-quality studies met the criteria for meta-analysis, including 2 RCTs and 5 cohort studies, with a total of 1165,738 patients. Compared with the control group, we found that incretin-based drugs reduced the relative risk of PCa by 35% (95% confidence interval (CI), 0.17-0.49; P = .0006). In subgroup analysis, the RR values for GLP-1 receptor agonists and DPP-4 inhibitors were 62% (95% CI, 0.45-0.85; P = .003) and 72% (95% CI, 0.46-1.12; P = .14), respectively. Incretin-based drugs are associated with lower incidence of prostate cancer and may have a preventive effect on prostate cancer in patients with type 2 diabetes.

基金机构：　

基金资助正文：